[
    [
        {
            "time": "",
            "original_text": "华东医药：公司拥有全资子公司英国Sinclair、西班牙High Tech以及参股公司美国R2、瑞士Kylane四个研发中心，及荷兰、法国、美国、瑞士和保加利亚五个生产基地，核心产品已在全球60多个国家和地区上市",
            "features": {
                "keywords": [
                    "研发",
                    "生产基地",
                    "全球化"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：公司拥有全资子公司英国Sinclair、西班牙High Tech以及参股公司美国R2、瑞士Kylane四个研发中心，及荷兰、法国、美国、瑞士和保加利亚五个生产基地，核心产品已在全球60多个国家和地区上市",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "华东医药：3期临床工作，预计今年会完成整体受试者入组",
            "features": {
                "keywords": [
                    "临床试验",
                    "3期",
                    "进展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：3期临床工作，预计今年会完成整体受试者入组",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "华东医药：公司并未直接布局养老产业",
            "features": {
                "keywords": [
                    "养老产业",
                    "未布局"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "养老产业"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：公司并未直接布局养老产业",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "华东医药：目前公司GLP-1受体激动剂利拉鲁肽注射液其糖尿病适应症以及减肥适应症在国内均在开展3期临床研究",
            "features": {
                "keywords": [
                    "GLP-1",
                    "利拉鲁肽",
                    "3期临床",
                    "糖尿病",
                    "减肥"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：目前公司GLP-1受体激动剂利拉鲁肽注射液其糖尿病适应症以及减肥适应症在国内均在开展3期临床研究",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华东医药（000963.SZ）：控股股东解除质押1952万股",
            "features": {
                "keywords": [
                    "解除质押",
                    "控股股东",
                    "股票"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "资本市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药（000963.SZ）：控股股东解除质押1952万股",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医美概念板块再度拉升 ，留给跨界者的空间还有多大？",
            "features": {
                "keywords": [
                    "医美",
                    "概念板块",
                    "拉升"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美",
                    "资本市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医美概念板块再度拉升 ，留给跨界者的空间还有多大？",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "华东医药现1笔大宗交易 共成交4,373.44万元",
            "features": {
                "keywords": [
                    "大宗交易",
                    "成交额"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "资本市场"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华东医药现1笔大宗交易 共成交4,373.44万元",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "华东医药今日大宗交易成交93.29万股，成交价46.88元折价4.68%",
            "features": {
                "keywords": [
                    "大宗交易",
                    "折价",
                    "成交量"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "资本市场"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华东医药今日大宗交易成交93.29万股，成交价46.88元折价4.68%",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "-中国医美行业调研简报：市场简报，医美注射剂快速发展，爱美客、华东医药、华熙生物及昊海生物哪家强【行业研究】",
            "features": {
                "keywords": [
                    "医美注射剂",
                    "行业研究",
                    "竞争分析"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "-中国医美行业调研简报：市场简报，医美注射剂快速发展，爱美客、华东医药、华熙生物及昊海生物哪家强【行业研究】",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]